| Variables |
NVP group n=71 |
LPV/r group n=94 |
p |
| Age(years)* |
42 (38-45) |
41 (37-44) |
0.2 |
| Male gender no. (%) |
47 (66) |
76 (81) |
0.03 |
| Body mass index (Kg/m2)* |
22.8 (20.5-24.4) |
23.2 (21.7-24.9) |
0.5 |
| HCV infection |
|
|
|
| Former IDU no. (%) |
55 (76) |
81 (86) |
0.1 |
| Baseline HCV-RNA <600000 IU/mL no. (%) |
40 (56) |
25 (27) |
0.001 |
| Cirrhosis no.(%)† |
3 (6) |
22 (32) |
0.001 |
| Baseline serum ALT(IU/L)* |
71 (45-100) |
69 (45-100) |
0.8 |
| HCV genotype no. (%) |
|
0.8 |
| 1 |
32 (45) |
47 (50) |
|
| 2 |
1 (1) |
2 (2) |
| 3 |
26 (37) |
32 (34) |
| 4 |
12 (17) |
13 (14) |
| HCV therapy |
|
|
|
| Use of peg-IFN alfa-2a no.(%) |
52 (73) |
78 (83) |
0.1 |
| RBV dose/weight (mg/Kg/day)* |
15.3 (13.8-16.4) |
14.5 (13.4-16.1) |
0.1 |
| Starting HCV therapy from 2000 to 2004 no. (%) |
25 (35) |
26 (28) |
0.3 |
| Peg-IFN plus RBV during 24 weeks no. (%) |
11 (15) |
10 (11) |
0.3 |
| Time from starting NVP or LPV/r to beginning HCV therapy (months)* |
39 (26-66) |
20 (10-29) |
0.001 |
| Compliance with HCV therapy≥80% no. (%) |
65 (91) |
83 (88) |
0.5 |
| Use of growth factors no. (%) |
3 (4) |
10 (11) |
0.1 |
| HIV infection |
|
|
|
| CDC C Clinical category no. (%) |
14 (20) |
32 (34) |
0.04 |
| Time with undetectable HIV viral load before starting HCV therapy (months)* |
62 (29-84) |
24 (14-58) |
0.002 |
| Baseline CD4 cell counts/mm3* |
489 (338-658) |
445 (300-589) |
0.3 |
| Baseline undetectable HIV viral load, no. (%) |
68 (95) |
77 (82) |
0.007 |
| Baseline LDL-cholesterol (mg/dL)* |
100 (85-122) |
84 (70-109) |
0.07 |
| Use of FTC no. (%) |
26 (37) |
35 (37) |
0.9 |
*Median (Q1-Q3); † Liver biopsy was available in 47 individuals in the nevirapine (NVP) group and in 69 subjects in the lopinavir/ritonavir (LPV/r) group. IDU: intravenous
drug user. ALT: alanine aminotransferase. peg-IFN: pegylated interferon. RBV: ribavirin. LDL: low-density lipoprotein. FTC: emtricitabine.